Literature DB >> 27627592

Applicability of first-trimester combined screening for fetal trisomy 21 in a resource-limited setting in mainland China.

B Li1, D S Sahota2, T T Lao2, J Xu1, S Q Hu1, L Zhang1, Q Y Liu1, Q Sun1, D Tang1, R M Ma3.   

Abstract

OBJECTIVE: To assess the feasibility and performance of the first-trimester combined screening test for trisomy 21 in a resource-limited setting in mainland China.
DESIGN: Prospective observational cohort study.
SETTING: First Affiliated Hospital of Kunming Medical University, China. POPULATION: Ten thousand four hundred and forty-two pregnant women requesting first-trimester screening.
METHODS: The combined screening test was performed from May 2012 to December 2014. Women with a high-risk result (≥1:600) were offered further confirmatory tests after counselling. The threshold for high risk was determined by Monte Carlo simulation to achieve a 5% false-positive rate according to the local age distribution. Pregnancy outcome and screening results were recorded for all women and monthly audits were conducted. MAIN OUTCOME MEASURES: Sensitivity, screen positive rate, cost per case of Down syndrome detected.
RESULTS: Six hundred and ten women (5.8% of the total screened) had a high-risk screening test, of whom 274 (44.9%) underwent a diagnostic test and 169 (27.7%) opted for a noninvasive prenatal screening test (NIPT); 160 (26.2%) declined further testing after counselling. The pregnancy outcome was available for 10 174 (97.4%) of the women. The observed incidence of Down syndrome was 0.13% (1/750). All 14 women with a trisomy 21 pregnancy had a high-risk screening test result. The cost per Down syndrome detected was RMB596 686 compared with RMB1.79 million if all had been screened by NIPT.
CONCLUSIONS: The combined screening test appears to be a more cost-effective strategy in mainland China. Screening performance in China would be improved by adopting Chinese-specific models, external quality control and assurance, and establishing risk thresholds appropriate for the age distribution of the population. TWEETABLE ABSTRACT: Combined first-trimester Downs screening in China was improved by adopting Chinese-specific models and external QC.
© 2016 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  China; Down syndrome; cost-effectiveness; first-trimester screening; noninvasive prenatal testing; nuchal translucency; 中国; 唐氏综合征; 成本效益; 早孕期联合筛查; 非侵入性产前检测; 颈项透明层

Mesh:

Substances:

Year:  2016        PMID: 27627592     DOI: 10.1111/1471-0528.14004

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  4 in total

1.  A risk model of prenatal screening markers in first trimester for predicting hypertensive disorders of pregnancy.

Authors:  Yiming Chen; Zhen Xie; Xue Wang; Qingxin Xiao; Xiao Lu; Sha Lu; Yezhen Shi; Shaolei Lv
Journal:  EPMA J       Date:  2020-06-19       Impact factor: 6.543

2.  A Retrospective Analysis Of Different Contingent Screening Models For Fetal Down Syndrome In Southwestern China.

Authors:  Wei Luo; Bin He; Daiwen Han; Lixing Yuan; Xinlian Chen; Ling Pang; Jun Tang; Fene Zou; Kai Zhao; Yepei Du; Hongqian Liu
Journal:  Sci Rep       Date:  2020-06-11       Impact factor: 4.379

3.  A Risk Model for Predicting Fetuses with Trisomy 21 Using Alpha-Fetoprotein Variants L2 Combined with Maternal Serum Biomarkers in Early Pregnancy.

Authors:  Yiming Chen; Bin Wu; Yijie Chen; Wenwen Ning; Huimin Zhang
Journal:  Reprod Sci       Date:  2021-11-08       Impact factor: 3.060

4.  Targeted capture enrichment followed by NGS: development and validation of a single comprehensive NIPT for chromosomal aneuploidies, microdeletion syndromes and monogenic diseases.

Authors:  George Koumbaris; Achilleas Achilleos; Michalis Nicolaou; Charalambos Loizides; Kyriakos Tsangaras; Elena Kypri; Petros Mina; Carolina Sismani; Voula Velissariou; Georgia Christopoulou; Pantelis Constantoulakis; Emmanouil Manolakos; Ioannis Papoulidis; Danai Stambouli; Marios Ioannides; Philippos Patsalis
Journal:  Mol Cytogenet       Date:  2019-11-21       Impact factor: 2.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.